GSK189075 + norgestrel + ethinylestradiol

GSK189075 + norgestrel + ethinylestradiol is a combination investigational drug. **Norgestrel** is a synthetic progestin, and **ethinylestradiol** is a synthetic estrogen; both are widely used in oral contraceptives to inhibit ovulation and produce changes to cervical mucus and the endometrium, resulting in contraceptive effects[1][2][4]. **GSK189075** is a GlaxoSmithKline developmental candidate, but public sources contain limited information on its mechanism, role, or stage of development in combination with these established contraceptive agents. The combination likely aims to provide contraception, with possible added novel benefit or feature contributed by GSK189075.